Other drug therapy and atherosclerotic cardiovascular disease risk

Annual influenza vaccination is recommended in all patients and is associated with a significant reduction in the risk of cardiovascular events in patients with ASCVD. Ensure patients are also up to date with other vaccinations¹.

Glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to lower ASCVD risk in patients with type 2 diabetesVisseren, 2021. Consider using a GLP-1 receptor agonist or SGLT2 inhibitor in patients with type 2 diabetes and who are at high absolute ASCVD risk or have established ASCVD (see Antihyperglycaemic drugs for secondary prevention of atherosclerotic cardiovascular disease)Australian Diabetes Society (ADS), 2022 Visseren, 2021.